Main Content start here
Main Layout
Report Description

Report Description

Malaysia diagnostic labs market stood at USD 1011.24 Million in 2021 and is expected to reach a CAGR of 7.89% during the forecast period. The rise in non-communicable diseases is increasing the demand for regular check-ups and multiple tests. In Malaysia, the prevalence of non-communicable diseases (NCDs) has increased during the last two decades. According to Novartis Malaysia, non-communicable diseases are responsible for 74% of all fatalities in Malaysia. In addition to the contagious COVID-19 virus, people with non-communicable diseases are more likely to experience additional consequences that can dramatically deteriorate their health. Initiated by Novartis Malaysia, the "NCDs in the New Normal" workshop aims to actively educate patients, caregivers, and the public to manage their health.

Furthermore, the rise in the geriatric population of Malaysia is another factor associated with non-communicable diseases. According to a declaration made by Malaysia's Chief Statistician in July 2019, there will be an increase of 15% in the current geriatric population by 2030. Malaysia's age distribution has changed during the last ten years. The percentage of people aged 0 to 14 has been rapidly declining, but the opposite was true for people 65 and older. This trend was reflected by the average age of the Malaysian population, which was projected to rise from 28.2 years in 2015 to 34.1 years in 2030. Due to changes in dietary habits, poor dentition, and amounts of food consumed, malnutrition is also a major problem in the elderly of the nation. The growing aging population and the rise of non-communicable diseases in the country will lead to more visits to diagnostic centers for disease diagnosis before hospitalization, enhancing the growth of the Malaysia diagnostic labs market.

Use of Digital Pathology to Augment Pathological Diagnosis

Digital pathology boosts productivity and efficiency, which helps pathologists to assess and cooperate quickly, remotely, transparently, and consistently. In the long run, computer-assisted diagnosis (CAD) and personalized care may all be a future of digital pathology. Pathologists can specialize in big data software, which extracts information from many data sets at once. This software can easily manage data for teaching and training and enables the expansion of practices to more geographically diverse areas. As a result of the development of digital pathology, pathologists can now operate remotely and collaborate with other professionals when a second opinion is required because digital pictures are saved on secure servers and can be viewed on computer monitors. Using digital pathology speeds up productivity and allows quicker diagnosis.

Growth in Medical Tourism

Malaysia is now considered one of Asia's most perceived emerging nations for medical tourism. Patients worldwide are running to Malaysia for great medical care administration. Malaysia has many bests in-class private physicians focusing on the different scopes of cutting-edge symptomatic, remedial, and in-patient administrations. Individuals are selecting Malaysia for medical assistance and treatment administrations. The government of Malaysia has allowed tax cuts, a change in tax law that works by reducing the amount of tax a person pays, hence advancing the growth of the clinical and travel industry in medical tourism. Medical care in Malaysia is under the Ministry of Health (MOH) domain. Malaysia has become one of the best options for unfamiliar patients looking for all medical services abroad.

Demand of Genetic Testing

Expanding interest in genetic testing also drives the market. Genetic testing helps patients make significant choices in the treatment or early discovery of genetic problems. The high occurrence rate of irresistible illnesses in Malaysia, as well as developing attention to the significance of early diagnosis and accuracy in test analysis, is expanding the patients' visits to diagnostic laboratories for testing.

Government Initiatives for Investment in Healthcare Sector

Malaysia's government plans to advance market development by investing in multiple sectors like developing drug and diagnostic tools, clinical research facilities, and diagnostic laboratories. A-Bio has contributed a whooping amount of USD1.8 million to Clinipath Malaysia Sdn. Bhd. (Clinipath) to catalyze the digitalization of the medical care industry in Malaysia. Malaysia has a strategy of all-inclusive wellbeing inclusion. The public authority/government plans to give sponsored medical care at minimum charges. The sponsored plans are looked after and managed by the Ministry of Health (MOH) through its government, state, and local offices. General health check-ups conducted by the government of Malaysia are on the rise, presenting a possible chance of market growth.


DOWNLOAD FREE SAMPLE REPORT

Market Segmentation

The Malaysia diagnostic labs market is segmented based on provider type, test type, end user, and regions distribution. Based on provider type, the market can be split among hospital based diagnostic labs, diagnostic chains, and stand-alone diagnostic labs. Based on test type, the market can be divided into pathology and radiology. In terms of end users, the market can be categorized into referrals, walk-ins, and corporate clients.

Company Profiles

Pantai Premier Pathology Sdn Bhd, Sunway Medical Centre, Lablink (M) Sdn Bhd, Pathology & Clinical Laboratory (M) Sdn. Bhd., Quantum Diagnostics Sdn Bhd, B.P. Clinical Lab Sdn. Bhd. (BP Lab), Innoquest Pathology, Clinipath Malaysia Sdn. Bhd., Neogenix Laboratoire Sdn Bhd, Sysmex Malaysia Sdn. Bhd.

Attribute

Details

Market size value in 2021

USD1011.24 Million

Revenue Forecast in 2027

USD1643.30 Million

Base Year

2021

Historical Years

2017 – 2021

Estimated Year

2022

Forecast Period

2023 – 2027

Quantitative Units

Revenue in USD Million, and CAGR for 2017-2021 and 2022E-2027F

Report Coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered

·         Provider Type

·         Test Type

·         End User

Regional Scope

West; East

Key Companies Profiled

Pantai Premier Pathology Sdn Bhd, Sunway Medical Centre, Lablink (M) Sdn Bhd, Pathology & Clinical Laboratory (M) Sdn. Bhd., Quantum Diagnostics Sdn Bhd, B.P. Clinical Lab Sdn. Bhd. (BP Lab), Innoquest Pathology, Clinipath Malaysia Sdn. Bhd., Neogenix Laboratoire Sdn Bhd, Sysmex Malaysia Sdn. Bhd.

Customization Scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and Purchase Options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/pdf format on special request)

 

Report Scope:

In this report, Malaysia diagnostic labs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Malaysia Diagnostic Labs Market, By Provider Type:
    • Hospital Based Diagnostic Labs
    • Diagnostic Chains
    • Stand Alone Diagnostic Labs
  • Malaysia Diagnostic Labs Market, By Test Type:
    • Pathology
    • Radiology
  • Malaysia Diagnostic Labs Market, By End User:
    • Referrals
    • Walk-ins
    • Corporate Clients
  • Malaysia Diagnostic Labs Market, By Region:
    • West Malaysia
    • East Malaysia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Malaysia diagnostic labs market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
Table of content

Table of content

1.    Service Overview

2.    Research Methodology

3.    Executive Summary

4.    Impact of COVID-19 on Malaysia Diagnostic Labs Market

5.    Voice of Customer

5.1.  Brand Awareness

5.2.  Factors affecting Choice of Diagnostic Laboratory

5.3.  Preference among population, By Provider Type

6.    Malaysia Diagnostic Labs Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Provider Type (Hospital Based Diagnostic Labs, Diagnostic Chains, Stand Alone Diagnostic Labs)

6.2.2.     By Test Type (Pathology v/s Radiology)

6.2.3.     By End User (Referrals, Walk-ins, Corporate Clients)

6.2.4.     By Region

6.2.5.     By Company (2021)

6.3.  Product Market Map

7.    Malaysia Hospital Based Diagnostic Labs Market Outlook

7.1.  Market Size & Forecast       

7.1.1.By Value

7.2.  Market Share & Forecast

7.2.1.     By Test Type

7.2.2.     By End User

8.    Malaysia Diagnostic Chains Market Outlook

8.1.  Market Size & Forecast       

8.1.1.By Value

8.2.  Market Share & Forecast

8.2.1.     By Test Type

8.2.2.     By End User

9.    Malaysia Stand Alone Diagnostic Labs Market Outlook

9.1.  Market Size & Forecast       

9.1.1.By Value

9.2.  Market Share & Forecast

9.2.1.     By Test Type

9.2.2.     By End User

10. Market Dynamics

10.1.             Drivers

10.2.             Challenges

11. Market Trends & Developments

12. Policy & Regulatory Landscape

13. Malaysia Economic Profile

14. Digitalization Across Laboratories in Malaysia

15. List of Diagnostic Labs in Malaysia, By Region

16. Pricing Analysis of Common Tests Offered By Top 5 Companies

17. Competitive Landscape

17.1.             Pantai Premier Pathology Sdn Bhd

17.2.             Sunway Medical Centre

17.3.             Lablink (M) Sdn Bhd

17.4.             Pathology & Clinical Laboratory (M) Sdn. Bhd.

17.5.             Quantum Diagnostics Sdn Bhd

17.6.              B.P. Clinical Lab Sdn. Bhd. (BP Lab)

17.7.             Innoquest Pathology Sdn. Bhd

17.8.             Clinipath (M) Sdn. Bhd

17.9.             Neogenix Laboratories Sdn Bhd

17.10.          Sysmex (M) Sdn Bhd 

18.  Strategic Recommendations

Figures and Tables

Figure 1: Malaysia Diagnostic Labs Market Size, By Value (USD Million), 2017-2027F

Figure 2: Malaysia Diagnostic Labs Market Share, By Provider Type, By Value, 2017-2027F

Figure 3: Malaysia Diagnostic Labs Market Share, By Test Type, By Value, 2017-2027F

Figure 4: Malaysia Diagnostic Labs Market Share, By End User, By Value, 2017-2027F

Figure 5: Malaysia Diagnostic Labs Market Share, By Region, By Value, 2017-2027F

Figure 6: East Malaysia Diagnostic Labs Market Share, By Value, 2017-2027F

Figure 7: West Malaysia Diagnostic Labs Market Share, By Value, 2017-2027F

Figure 8: Malaysia Diagnostic Labs Market Share, By Company, By Value, 2021

Figure 9: Malaysia Diagnostic Labs Market Map, By Provider Type, Market Size (USD Million) & Growth Rate (%), 2021

Figure 10: Malaysia Diagnostic Labs Market Map, By Test Type, Market Size (USD Million) & Growth Rate (%), 2021

Figure 11: Malaysia Diagnostic Labs Market Map, By End User, Market Size (USD Million) & Growth Rate (%), 2021

Figure 12: Malaysia Diagnostic Labs Market Map, By Region, Market Size (USD Million) & Growth Rate (%), 2021

Figure 13: Malaysia Hospital Based Diagnostic Labs Market Size, By Value (USD Million), 2017-2027F

Figure 14: Malaysia Hospital Based Diagnostic Labs Market Share, By Test Type, By Value, 2017-2027F

Figure 15: Malaysia Hospital Based Diagnostic Labs Market Share, By End User, By Value, 2017-2027F

Figure 16: Malaysia Diagnostic Chains Market Size, By Value (USD Million), 2017-2027F

Figure 17: Malaysia Diagnostic Chains Market Share, By Test Type, By Value, 2017-2027F

Figure 18: Malaysia Diagnostic Chains Market Share, By End User, By Value, 2017-2027F

Figure 19: Malaysia Stand Alone Diagnostic Labs Market Size, By Value (USD Million), 2017-2027F

Figure 20: Malaysia Stand Alone Diagnostic Labs Market Share, By Test Type, By Value, 2017-2027F

Figure 21: Malaysia Stand Alone Diagnostic Labs Market Share, By End User, By Value, 2017-2027F
Frequently asked questions

Frequently asked questions

Malaysia diagnostic labs market is expected to witness an impressive growth of 7.89% and reach USD1643.30 million by 2027.

In 2021, pathology tests were more preferred than radiology tests and occupied a share of 60.72%. Pathology is more in demand than radiology because most communicable diseases require an early diagnosis to reduce the spreading of the disease.

Use of digital technology, demand of genetic testing, government investment in healthcare sector, etc. are the drivers of Malaysia diagnostic labs market.

The COVID-19 impact surged the market of diagnostic labs in Malaysia as well as globally, as more demand for precise and accurate testing were required for treatment which also enabled patients to know about rapid diagnostic methods.

Related Reports